Stock screener

RXRX

Conviction 61HealthcareScan · Thu, Sep 24, 2026

Recursion Pharmaceuticals, Inc. (RXRX) closed at $3.89 (+5.00%) on Sep 24, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 59, RS Rating 47, -42.8% from its 52-week high, -7.5% year to date. Sector: Healthcare · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES).

RXRX$3.89+5.00%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 22.97M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
RECURSION PHARMACEUTICALS, INC.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.recursion.com ↗
Price3.89
Change+5.00%
Gap-0.68%
Rel volume1.39×
Avg volume19.74M
Avg $ vol71.41M
SMA 203.49
SMA 503.30
SMA 2003.59
Price vs 50+17.70%
Price vs 200+8.18%
MA stackmixed
50/200 cross—
Supertrendup · 3.36
RSI (14)59
MACD hist0.06
MACD crossbull · 4d
Stoch %K / %D74 / 73
ADX (14)20
+DI / −DI33 / 20
RSI divergence—
MACD divergenceBearish
ATR %6.05%
ADR %5.99%
52w high6.79
52w low2.84
From 52w high-42.78%
Above 52w low+36.80%
New 52w highNo
SqueezeOff
Bollinger width30.17%
%B0.88
Donchian pos74.06%
Donchian high4.16
Donchian low3.10
AVWAP (52w high)4.03
vs AVWAP high-3.71%
AVWAP (52w low)3.40
vs AVWAP low+14.41%
OBV trendUp
Chaikin MF (20)0.21
Today vs 20d1.39×
Avg vol (14d)22.97M
Avg vol (20d)19.74M
Avg $ vol (20d)71.41M
Market cap2.08B
RS Rating47 / 99
RS 3m (vs SPY)+11.83%
RS 6m (vs SPY)+5.74%
RS line new highNo
Trend template4/8
Technical rank83.4
1 week+9.75%
1 month+9.13%
3 months+16.32%
6 months+22.56%
1 year-19.23%
YTD-7.50%
P/E-3.23
P/B2.27
P/S27.85
P/FCF-5.50
EPS-1.44
Div yield—
ROE-70.47%
ROA-53.17%
Debt/Eq0.00
Current5.03
EV/EBITDA-2.72
Gross margin—
Net margin-863.35%
Rev growth26.92%
EPS growth-39.06%
Price target6.65
Target upside71.17%
Analyst ratingHold
Institutional78.99%
Ent. value1.53B
Revenue7.67M
Net income-131M
Gross profit—
Free cash flow-378.28M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out524.68M
Employees600
ListedFri, Apr 16, 2021
Free float409.84M
Float %78.5%
Short interest179.15M
Days to cover10.6d
Short volume57.8%
Squeeze score83 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.25 vs −$0.23
Last surprise-8.7% miss
Setup gradeB
Conviction61 / 100
Pattern quality—
Tech rank83.4 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance3.93
Support3.01
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Recent news

Congress activity

Disclosed STOCK Act trades in RXRX

All disclosures →
No recent disclosed trades by Congress in RXRX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RXRX · open-market 4 sells

InsiderSideShares
Borgeson Blake
Director · Class A Common Stock · 2026-09-01
Sell30K
Khan Najat
CEO and President · Class A Common Stock · 2026-08-17
Tax80.5K
Taylor Ben R
Chief Financial Officer · Class A Common Stock · 2026-08-17
Tax25.02K
Hallett David
Chief Scientific Officer · Class A Common Stock · 2026-08-17
Tax26.66K
Borgeson Blake
Director · Class A Common Stock · 2026-08-04
Sell30K
Borgeson Blake
Director · Class A Common Stock · 2026-07-07
Sell40K
Bumpus Namandje
Director · Class A Common Stock · 2026-06-18
Sell3.96K
Michor Franziska
Director · Class A Common Stock · 2026-06-17
Grant88.42K
Sun Elaine D
Director · Class A Common Stock · 2026-06-17
Grant88.42K
Li Dean Y
Director · Class A Common Stock · 2026-06-17
Grant88.42K

SEC filings

EDGAR filings in RXRX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.